Denervation supersensitivity in the mesolimbic system: involvement of dopamine-stimulated adenylate cyclase.
Explore the source record for details and available documents.
Biomedical subjects
Publications and source records attributed to E L Gardner.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Unilateral radiofrequency lesions or chemical lesions with 6-hydroxydopamine were produced in the substantia nigra of rat brain in order to destroy dopaminergic innervations to caudate nucleus and thereby to produce functional denervation supersensitivity. Both types of lesions resulted in enhanced stimulation of caudate adenylate cyclase (EC 4.6.1.1) activity by dopamine at all dopamine concentrations tested, with more marked enhancement at the lower concentrations. Response to another dopamine agonist, 1-(3,4-dihydroxybenzyl)-4-(20pyrimidinyl) piperazine (S584) was also enhanced. 6-Hydroxydopamine lesions resulted in selective enhancement of the dopamine-stimulated component of adenylate cyclase, whereas radiofrequency lesions resulted also in a marked decrease in basal activity. It is postulated that the basal activity of caudate represents primarily an adenylate cyclase distinct from that stimulated by dopamine and destroyed only by the less selective radiofrequency lesion. The enhancement of dopamine-sensitive adenylate cyclase after lesions serves as indirect evidence for a significant role of this system in the transmitter function of dopamine and indicates, furthermore, that it is directly involved in dopamine receptor supersensitivity in vivo produced by denervation.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
The effect of haloperidol treatment on human plasma levels of magnesium (Mg), calcium (Ca) and phosphorus (P) was assessed. Haloperidol treatment significantly reduced plasma Mg but not plasma Ca or P levels. This finding contrasts with studies using other neuroleptics where reductions in both Mg and Ca concentrations were observed. The addition of lithium to haloperidol treatment resulted in an elevation of plasma Mg, but not Ca or P, to levels significantly greater than those at baseline. The reduction of Mg levels by haloperidol may reflect the ion's involvement in the pathology of psychosis and/or in the mechanism of generating extrapyramidal side effects.
Explore the source record for details and available documents.